Animal models of human diseases that accurately recapitulate clinical pathology are
indispensable for understanding molecular mechanisms and advancing preclinical studies …

Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of
evidence from laboratories and clinics worldwide support the concept that an imbalance …

Introduction: Molecular dynamics (MD) simulations can provide not only plentiful dynamical
structural information on biomacromolecules but also a wealth of energetic information …

The first description of Alzheimer's disease (AD) was made in 1907 by Alois Alzheimer
(Allgemeine Zeitschrift fur Psyciatrie und Psychisch‐Gerichtliche Medizin 64, 3, 1907) …

Alzheimer's disease (AD) challenges our society with an annual estimated cost of $1.08
trillion in the United States alone by 2050. 1 AD is a progressive irreversible neurological …

Abstract β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the β-secretase
enzyme required for the production of the neurotoxic β-amyloid (Aβ) peptide that is widely …

Deficiency in cerebral amyloid β-protein (Aβ) clearance is implicated in the pathogenesis of
the common late-onset forms of Alzheimer's disease (AD). Accumulation of misfolded Aβ in …

To provide better prevention and treatment, we need to understand the environmental and
genetic risks of Alzheimer's disease (AD). However, the definition of AD has been …

β-Amyloid (Aβ) peptides are thought to be critically involved in the etiology of Alzheimer's
disease (AD). The aspartyl protease β-site amyloid precursor protein cleaving enzyme 1 …

Amyloid precursor protein (APP) is a key player in Alzheimer's disease (AD). The Aβ
fragments of APP are the major constituent of AD-associated amyloid plaques, and …